Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-09-2017 | Original Article

Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis

Authors: Thomas J. W. Klein Nulent, Robert J. J. van Es, Gerard C. Krijger, Remco de Bree, Stefan M. Willems, Bart de Keizer

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2017

Abstract

Background

Adenoid cystic carcinoma (AdCC) of the head and neck is an uncommon malignant epithelial tumour of the secretory glands. Many patients develop slowly growing local recurrence and/or distant metastasis, for which treatment options are limited. A retrospective analysis of 9 AdCC patients was conducted to analyse the visualization of AdCC on PSMA PET/CT and to investigate the expression of PSMA on primary, recurrent and metastatic AdCC tumour tissue using immunohistochemistry.

Results

Local recurrence occurred in six patients and eight developed distant metastasis. All PET/CTs depicted PSMA-ligand uptake. Four PSMA PET/CTs showed suspected residual disease, eight scans depicted uptake in areas suspected of distant metastasis. Median Maximum Standardized Uptake Value (SUV_max) in local recurrent and distant metastatic AdCC was 2.52 (IQR 2.41–5.95) and 4.01 (IQR 2.66–8.71), respectively. All primary tumours showed PSMA expression on immunohistochemistry (5–90% expression), as well as all available specimens of local recurrence and distant metastases.

Conclusion

PSMA PET/CT is able to detect and visualize local recurrent and distant metastatic AdCC. PSMA-specific targeting is supported by PSMA expression on immunohistochemistry.

Coca-Pelaz A, Rodrigo JP, Bradley PJ, Vander Poorten V, Triantafyllou A, Hunt JL, et al. Adenoid cystic carcinoma of the head and neck - an update. Oral Oncol. 2015;51:652–61.

Bjørndal K, Krogdahl A, Therkildsen MH, Overgaard J, Johansen J, Kristensen CA, et al. Salivary gland carcinoma in Denmark 1990-2005: a national study of incidence, site and histology. Results of the Danish head and neck cancer Group (DAHANCA). Oral Oncol. 2011;47(7):677–82.CrossRefPubMed

Netherlands Comprehensive Cancer Organisation, The Netherlands Cancer Registry. Incidence of invasive salivary gland cancer per year. 2015 [cited 2016 Apr 1]. Available from: http://www.cijfersoverkanker.nl

Hellquist H, Skalova A. Adenoid Cystic Carcinoma. In: Histopathology of the Salivary Glands. Springer Berlin Heidelberg; 2014. p. 221–60.

Spiro RH, Huvos AG, Strong EW. Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases. Am J Surg. 1974;128(4):512–20.CrossRefPubMed

Freling N, Crippa F, Maroldi R. Staging and follow-up of high-grade malignant salivary gland tumours: the role of traditional versus functional imaging approaches - a review. Oral Oncol. 2016;60:157–66.CrossRefPubMed

Jung JH, Lee SW, Son SH, Kim CY, Lee CH, Jeong JH, et al. Clinical impact of (18) F-FDG positron emission tomography/CT on adenoid cystic carcinoma of the head and neck. Head Neck. 2017;39(3):447–55.CrossRefPubMed

Van Weert S, Reinhard R, Bloemena E, Buter J, Witte BI, Vergeer MR, et al. Differences in patterns of survival in metastatic adenoid cystic carcinoma of the head and neck. Head Neck. 2017;39(3):456–63.CrossRefPubMed

Ciccolallo L, Licitra L, Cantú G, Gatta G. Survival from salivary glands adenoid cystic carcinoma in European populations. Oral Oncol. 2009;45(8):669–74.CrossRefPubMed

10.

Terhaard CHJ, Lubsen H, Van Der Tweel I, Hilgers FJM, Eijkenboom WMH, Marres HAM, et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck Oncology cooperative Group. Head Neck. 2004;26(8):681–92.CrossRefPubMed

11.

Horoszewicz JS, Kawinsky EMG. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7(5B):927–35.PubMed

12.

Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993;53(2):227–30.PubMed

13.

Wright GL, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol Semin Orig Investig. 1995;1(1):18–28.CrossRef

14.

Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The novel theranostic PSMA-ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry and first evaluation of tumor lesions. J Nucl Med. 2015;56(11):1697–705.CrossRefPubMed

15.

Rischpler C, Maurer T, Schwaiger M, Eiber M. Intense PSMA-expression using 68Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis. Eur J Nucl Med Mol Imaging. 2016;43(1):193–4.CrossRefPubMed

16.

Ardies PJ, Gykiere P, Goethals L, De Mey J, De Geeter F, Everaert H. PSMA uptake in mediastinal sarcoidosis. Clin Nucl Med. 2017;42(4):303–5.CrossRefPubMed

17.

Jochumsen MR, Vendelbo MH, Høyer S, Bouchelouche K. Subcutaneous lobular capillary hemangioma on 68Ga-PSMA PET/CT. Clin Nucl Med. 2017;42(4):e214–5.CrossRefPubMed

18.

Artigas C, Alexiou J, Garcia C, Wimana Z, Otte F-X, Gil T, et al. Paget bone disease demonstrated on 68Ga-PSMA ligand PET/CT. Eur J Nucl Med Mol Imaging. 2016;43(1):195–6.CrossRefPubMed

19.

Kanthan GL, Hsiao E, Kneebone A, Eade T, Schembri GP. Desmoid tumor Showing intense uptake on 68Ga PSMA-HBED-CC PET/CT. Clin Nucl Med. 2016;41(6):508–9.CrossRefPubMed

20.

Kanthan GL, Drummond J, Schembri GP, Izard MA, Hsiao E. Follicular thyroid adenoma showing avid uptake on 68Ga PSMA-HBED-CC PET/CT. Clin Nucl Med. 2016;41(4):331–2.CrossRefPubMed

21.

Chan M, Schembri GP, Hsiao E. Serous cystadenoma of the pancreas showing uptake on 68Ga PSMA PET/CT. Clin Nucl Med. 2017;42(1):56–7.CrossRefPubMed

22.

Law WP, Fiumara F, Fong W, Miles KA. Gallium-68 PSMA uptake in adrenal adenoma. J Med Imaging Radiat Oncol. 2016;60(4):514–7.CrossRefPubMed

23.

Heitkötter B, Trautmann M, Grünewald I, Bögemann M, Rahbar K, Gevensleben H, et al. Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST. Oncotarget. 2017;8(3):4268–76.PubMed

24.

Kanthan GL, Coyle L, Kneebone A, Schembri GP, Hsiao E. Follicular lymphoma showing avid uptake on 68Ga PSMA-HBED-CC PET/CT. Clin Nucl Med. 2016;41(6):500–1.CrossRefPubMed

25.

Sasikumar A, Joy A, Pillai MRA, Nanabala R, Anees KM, Jayaprakash PG, et al. Diagnostic value of 68Ga PSMA-11 PET/CT imaging of brain tumors—preliminary analysis. Clin Nucl Med. 2017;42(1):e41–8.CrossRefPubMed

26.

Sathekge M, Lengana T, Modiselle M, Vorster M, Zeevaart J, Maes A, et al. 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. Eur J Nucl Med Mol Imaging. 2017;44(4):689–94.CrossRefPubMed

27.

Wang H, Wang S, Song W, Pan Y, Yu H, Si T, et al. Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance. PLoS One. 2015;10(5):e0125924.CrossRefPubMedPubMedCentral

28.

Demirci E, Ocak M, Kabasakal L, Decristoforo C, Talat Z, Halaç M, et al. 68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41(7):1461–2.CrossRefPubMed

29.

Verburg FA, Krohn T, Heinzel A, Mottaghy FM, Behrendt FF. First evidence of PSMA expression in differentiated thyroid cancer using [68Ga]PSMA-HBED-CC PET/CT. Eur J Nucl Med Mol Imaging. 2015;42(10):1622–3.CrossRefPubMed

30.

Sasikumar A, Joy A, Nanabala R, Pillai MRA, Thomas B, Vikraman KR. (68)Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2016;43(4):795–6.CrossRefPubMed

31.

Chang SS, Reuter VE, Heston WDW, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59(13):3192–8.PubMed

32.

Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Am Assoc Cancer Res. 1997;3(1):81–5.

33.

De Keizer B, Krijger GC, Ververs FT, van Es RJJ, de Bree R, Willems S. 68Ga-PSMA PET-CT imaging of metastatic adenoid cystic carcinoma. Nucl Med Mol Imaging (2010). 2016;8:1–2. Available from: doi:10.1007/s13139-016-0445-6

34.

Lütje S, Sauerwein W, Lauenstein T, Bockisch A, Poeppel TD. In vivo visualization of prostate-specific membrane antigen in adenoid cystic carcinoma of the salivary gland. Clin Nucl Med. 2016;41(6):476–7.CrossRefPubMed

35.

Perzin KH, Gullane P, Clairmont AC. Adenoid cystic carcinomas arising in salivary glands: a correlation of histologic features and clinical course. Cancer. 1978;42(1):265–82.CrossRefPubMed

36.

Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–54.CrossRefPubMed

37.

Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54(7):1807–11.PubMed

38.

Troyer JK, Beckett ML, Wright GL. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 1995;62(5):552–8.CrossRefPubMed

39.

Wolf P, Freudenberg N, Bühler P, Alt K, Schultze-Seemann W, Wetterauer U, et al. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate. 2010;70(5):562–9.PubMed

40.

Lonneux M, Hamoir M, Reychler H, Maingon P, Duvillard C, Calais G, et al. Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. J Clin Oncol. 2010;28(7):1190–5.CrossRefPubMed

41.

Kinahan PE, Fletcher JW. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR. 2010;31(6):496–505.CrossRefPubMedPubMedCentral

42.

Bjørndal K, Krogdahl A, Therkildsen MH, Charabi B, Kristensen CA, Andersen E, et al. Salivary adenoid cystic carcinoma in Denmark 1990-2005: outcome and independent prognostic factors including the benefit of radiotherapy. Results of the Danish head and neck cancer Group (DAHANCA). Oral Oncol. 2015;51(12):1138–42.CrossRefPubMed

43.

Fendler WP, Reinhardt S, Ilhan H, Delker A, Böning G, Gildehaus FJ, et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget. 2017;8(2):3581–90.PubMed

44.

Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2016;85(1):85–90.

45.

Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197–209.CrossRefPubMed

46.

Wernicke AG, Kim S, Liu H, Bander NH, Pirog EC. Prostate-specific membrane antigen (PSMA) expression in the neovasculature of gynecologic malignancies: implications for PSMA-targeted therapy. Appl Immunohistochem Mol Morphol AIMM. 2017;25:271–6.CrossRef

47.

Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et al. Targeted alpha therapy of mCRPC with (225)actinium-PSMA-617: dosimetry estimate and empirical dose finding. J Nucl Med. 2017;

Title: Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis
Authors: Thomas J. W. Klein Nulent
Robert J. J. van Es
Gerard C. Krijger
Remco de Bree
Stefan M. Willems
Bart de Keizer
Publication date: 01-09-2017
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-017-3737-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis

Abstract

Background

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2017

Effects of arm truncation on the appearance of the halo artifact in 68Ga-PSMA-11 (HBED-CC) PET/MRI

SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction?

A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy

Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence

Players of ‘hypoxia orchestra’ – what is the role of FMISO?

[18]Fluorodeoxyglucose Positron Emission Tomography for the Textural Features of Cervical Cancer Associated with Lymph Node Metastasis and Histological Type